ENTRY       D09371                      Drug
NAME        Ramucirumab (USAN);
            Ramucirumab (genetical recombination) (JAN);
            Cyramza (TN)
PRODUCT     CYRAMZA (Eli Lilly and Company)
FORMULA     C6374H9864N1692O1996S46
EXACT_MASS  143518.9522
MOL_WEIGHT  143607.6508
SEQUENCE    (Heavy chain)
            EVQLVQSGGG LVKPGGSLRL SCAASGFTFS SYSMNWVRQA PGKGLEWVSS ISSSSSYIYY
            ADSVKGRFTI SRDNAKNSLY LQMNSLRAED TAVYYCARVT DAFDIWGQGT MVTVSSASTK
            GPSVLPLAPS SKSTSGGTAA LGCLVKDYFP EPVTVSWNSG ALTSGVHTFP AVLQSSGLYS
            LSSVVTVPSS SLGTQTYICN VNHKPSNTKV DKRVEPKSCD KTHTCPPCPA PELLGGPSVF
            LFPPKPKDTL MISRTPEVTC VVVDVSHEDP EVKFNWYVDG VEVHNAKTKP REEQYNSTYR
            VVSVLTVLHQ DWLNGKEYKC KVSNKALPAP IEKTISKAKG QPREPQVYTL PPSREEMTKN
            QVSLTCLVKG FYPSDIAVEW ESNGQPENNY KTTPPVLDSD GSFFLYSKLT VDKSRWQQGN
            VFSCSVMHEA LHNHYTQKSL SLSPGK
            (Light chain)
            DIQMTQSPSS VSASIGDRVT ITCRASQGID NWLGWYQQKP GKAPKLLIYD ASNLDTGVPS
            RFSGSGSGTY FTLTISSLQA EDFAVYFCQQ AKAFPPTFGG GTKVDIKRTV AAPSVFIFPP
            SDEQLKSGTA SVVCLLNNFY PREAKVQWKV DNALQSGNSQ ESVTEQDSKD STYSLSSTLT
            LSKADYEKHK VYACEVTHQG LSSPVTKSFN RGEC
            (Disulfide bridge: H22-H96, H143-H199, H219-L214, H225-H'225, H228-H'228, H260-H320, H366-H424, H'22-H'96, H'143-H'199, H'219-L'214, H'260-H'320, H'366-H'424, L23-L88, L134-L194, L'23-L'88, L'134-L'194)
  TYPE      Peptide
REMARK      Therapeutic category: 4291
            ATC code: L01FG02
            Product: D09371<JP/US>
EFFICACY    Antineoplastic, Anti-VEGF receptor 2 antibody
  DISEASE   Gastric cancer [DS:H00018]
            Non-small cell lung cancer (EGFR exon 19 deletions or exon 21 (L858R) substitution mutated) [DS:H00014]
            Colorectal cancer [DS:H00020]
            Hepatocellular carcinoma [DS:H00048]
  TYPE      Monoclonal antibody
TARGET      VEGFR2 (KDR) [HSA:3791] [KO:K05098]
  PATHWAY   hsa01521(3791)  EGFR tyrosine kinase inhibitor resistance
            hsa04014(3791)  Ras signaling pathway
            hsa04370(3791)  VEGF signaling pathway
INTERACTION  
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
              L01 ANTINEOPLASTIC AGENTS
               L01F MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES
                L01FG VEGF/VEGFR (Vascular Endothelial Growth Factor) inhibitors
                 L01FG02 Ramucirumab
                  D09371  Ramucirumab (USAN) &lt;JP/US&gt;
            USP drug classification [BR:br08302]
             Antineoplastics
              Monoclonal Antibody/Antibody-Drug Conjugate
               Ramucirumab
                D09371  Ramucirumab (USAN)
            Therapeutic category of drugs in Japan [BR:br08301]
             4  Agents affecting cellular function
              42  Antineoplastics
               429  Miscellaneous
                4291  Other Antitumors
                 D09371  Ramucirumab (USAN); Ramucirumab (genetical recombination) (JAN)
            Target-based classification of drugs [BR:br08310]
             Protein kinases
              Receptor tyrosine kinases (RTK)
               VEGFR family
                VEGFR2 (KDR)
                 D09371  Ramucirumab (USAN) &lt;JP/US&gt;
            New drug approvals in the USA [br08319.html]
             New molecular entities and new therapeutic biological products
              D09371
            New drug approvals in Europe [br08329.html]
             European public assessment reports (EPAR) authorised medicine
              D09371
            New drug approvals in Japan [br08318.html]
             Drugs with new active ingredients
              D09371
            New drug approvals in the USA, Europe and Japan [br08328.html]
             Approval dates by FDA, EMA and PMDA
              D09371
            Pharmacogenomic biomarkers [br08341.html]
             Somatic variations in targeted cancer therapies
              D09371
DBLINKS     CAS: 947687-13-0
            PubChem: 96026051
///
